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Summary
Objectives To assess the use of an electronic dose calculator to
improve accuracy in the use of a complex Gentamicin prescription policy
and assess turnaround time of blood sampling to dose delivery in an NHS
hospital.
Design Retrospective review of drug chart, case notes and hospital
antibiotic database.
Setting University Hospitals Bristol, UK
Participants Patients receiving once daily intravenous gentamicin
using the trust protocol, during the same time window for 3 consecutive
years.
Main outcome measures i) Accuracy of dose and frequency
prescription of Gentamicin. ii) Time frame for measurement of serum
Gentamicin levels.
Results Following the introduction of the online calculator, prescribing
errors in obese patients dropped from 43% to 20%, a similar level as in
non-obese patients. Errors in frequency calculations dropped from 12.8%
to 4%. On average, drug doses could be administered within 2.5 hours of a
blood sample being taken.
Conclusions Online tools can be used to improve prescribing for the
complex dosing policies that will increasingly been required to tailor
prescribing in obese patients. Serum gentamicin levels can be measured
within a 2.5 hour time frame in the environment of an NHS hospital.
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RESEARCH
1Introduction
The increasing prevalence of obesity has led some
to question whether prescribing should be more
tailored to the individual, such that patients
receive dosages that will create plasma concen-
trations falling more reliably within therapeutic
ranges. In the ﬁeld of oncology we see that
therapy can be successfully personalized
through treatments matched to biomarkers
expressed by an individual,
1 and in cardiology
various methods have been utilized to personalize
antiplatelet therapy to allow individuals within
the population to achieve an equally effective
dosage.
2
Despite personalized care according to body
weight already being possible, the practicalities
of prescribing routine drugs on an individualized
basis on busy general surgical wards have hin-
dered the introduction of these advances.
Gentamicin, owing to its potent ototoxic and
nephrotoxic side effects, is a drug that has
always required individualized dose calculation
to some extent, with some trusts already having
a dosing protocol in place to dose patients based
on weight. However, gentamicin is a hydrophilic
drug that will undergo differential distribution
in the obese patient compared to patients with
normal body mass index, leading to over-dosing
in obese patients if prescribed according to
actual body weight.
3 Recently, Gentamicin has
regained popularity as antibiotic protocols have
been altered in an attempt to decrease the inci-
dence of drug associated clostridium difﬁcile
infection. In 2008, a new prescription protocol
was established at the Bristol Royal Inﬁrmary,
UK. Since obesity may affect 20–30% of patients,
4
the opportunity was taken to introduce a new cal-
culation policy that would more accurately dose
patients to improve safety, especially in these
obese patients. This required a series of step-wise
calculations to be carried out to determine the
patients ideal body weight, creatinine clearance
and dosing schedule.
It was also unknown if hospital systems would
be able to withstand the pressures imposed by a
regime that is reliant on staff to take a blood
sample at a speciﬁed time and transport it to path-
ology where it would be processed with sufﬁcient
speed to allow nursing staff to deliver subsequent
doses without delay. The success of the policy was
audited on three occasions, with changes made to
facilitate the use of the protocol by doctors at each
stage.
Two primary outcomes were identiﬁed for this
study. Firstly, to assess the extent to which an elec-
tronic online calculation tool can help improve
accuracy of drug prescription in obese patients
and secondly to assess the time taken for
systems within an NHS hospital to process genta-
micin levels.
Methods
Three audit cycles were undertaken over the same
time period each year and included all patients at
University Hospitals Bristol, UK, that had genta-
micin levels sent to pathology during the time
period August to September. This time period cor-
responds to the period when new junior doctors
start working at the trust. Inclusion criteria was
any patient receiving once daily intravenous gen-
tamicin using the trust protocol within the given
time window.
Prior to the introduction of the online calculator,
the patients’ ideal body weight (IBW) was calcu-
lated, with the aid of reference tables (Appendix,
Figures 1, 2), using the following formulae:
MALE IBW (kg) ¼
50 þð 2:3  ð height in inches   60ÞÞ
FEMALE IBW (kg) ¼
45:5 þð 2:3  ð height in inches   60ÞÞ
Patientswerecategorizedasobeseiftheirweight
was greater than 20% above IBW.
Non-obese patients received a standard dose of
5m g /kg rounded down to the nearest multiple
of 40. In obese patients, a ‘Dose-determining
weight’(DDW) was calculated using the formula:
DDW(kg) ¼ IBW þ 0:4
 ½ actual body weight (kg)  IBW :5
Gentamicin dose was then calculated by multi-
plying DDW(kg) by 5 mg, then rounding down to
the nearest multiple of 40. Reference tables were
made available to assist with this calculation
(Appendix, Figure 3).
Gentamicin was dosed daily according to this
protocol, except in patients with impaired renal
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Mubarak Al Amerifunction. To determine renal function, creatinine
clearance (CrCl) was calculated using the Cock-
croft Gault equation:
6
CrCl(ml/min) ¼ 140   age[yrs]   IBW[kg]
  1.23 [male] or 1.04 [female]=
serum creatinine½mmol/1 :
If CrCl was 40–59 μmol/l frequency reduced to
36 hourly and to 48 hourly in patients with CrCl
20–39 μmol/l. Patients with CrCl less than 20
were not suitable for Gentamicin.
The protocol required gentamicin levels to be
taken after the ﬁrst dose in all patients. Sub-
sequently, levels were required to be taken after
every dose in patients over 65 or with poor renal
function, but levels were not required to be
checked in patients with normal creatinine clear-
ance provided they were passing adequate
volumes of urine.
Following the ﬁrst audit cycle, an online calcu-
lator was produced and published on the hospital
intranet. This calculator required the input of a
patient’s age, sex, weight and serum creatinine,
in order to calculate dosage and frequency, and,
following the second audit cycle, the prescription
chart was altered to advertise this tool and remove
dosing formulas.
Each drug dose was assessed retrospectively by
one of the authors (JM,ARS,CT,SS,KS). Patients
were excluded if there was a documented reason
for the prescription not being dosed according to
protocol e.g. given according to microbiology
advice. Adults were included from all specialties.
The Bristol Royal Inﬁrmary online antibiotic
database which was set up to prior to the launch
of the antibiotic policy. This recorded specimen
processing activity including time of blood
sampling, time of arrival in the laboratory, Genta-
micin level result and time of level being available.
Data for each serum level taken was extracted
from this database by the authors (JM,ARS,CT,
SS,KS).
On the prescription form it was the responsibil-
ity of doctors to calculate dose using patient
weight and record creatinine clearance in order
to calculate frequency. These calculations were
often checked by pharmacists. It was the responsi-
bility of nurses to record the timing of blood
samples and record the dose given and the time
given. Doctors bore overall responsibility for the
correct use of the protocol.
The tests for statistical signiﬁcance were
performed using the SPSS 17.0 statistics program
(SPSS Inc. Chicago, IL, USA).
Results
A total of 334 Gentamicin doses were adminis-
tered during the 3 audit windows. The majority
of these being delivered to surgical patients, as
would be expected with the local prescribing
guidelines. Population size was 31 patients in the
2008 audit (17 non-obese, 14 obese), 32 patients
in the 2009 audit (20 non-obese, 12 obese) and 27
patients in the 2010 audit (17 non-obese, 10
obese). Overall, 40% of patients identiﬁed were
obese. The median age of patients was 59 (inter-
quartile range 40–72.5 yrs).
Over the 3 years, dosing accuracy in non-obese
patients remained fairly consistent with between
71 and 88% of patients having all doses correct.
In total, 22% of non-obese patients had a dose pre-
scribed incorrectly.
In 2008, 43% of obese patients received all doses
calculatedaccordingtoprotocol.In2009,thisﬁgure
was 42%. By 2010, this ﬁgure was 20% (Figure 1).
According to the protocol, frequency of pre-
scription can vary every dose as renal function
varies. As such, the total number of prescriptions
are reported rather than the number of patients
with all frequencies correct. The accuracy of fre-
quency prescription was difﬁcult to assess due to
occasional delays between prescription and
dosing. Although the prescription recorded the
planned time of the next dose and the time the
previous dose was given, the time of the prescrip-
tion was not always recorded and may differ from
the dosing time. As such, up to 65% of frequency
prescriptions could not be accurately assessed,
although cases in which errors were present
were easier to identify, primarily because most
changes require extending the period between
doses, leaving doses occurring early in spite of
any delays occurring on the ward. In the ﬁrst
cycle 13 of 107 (12.2%) of prescriptions were at
the incorrect frequency, 9 of which errors were in
obese patients; in the second cycle this was 4 of
106 (3.8%) with 3 in obese patients; and 3 of 75
(4%) in the third cycle, 2 of which were obese.
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3These results were signiﬁcantly different between
the 3 cycles (Pearson χ2 P =0.017) (Figure 2).
Median time for the drug level samplesto reach
pathology in the 3 audits varied between 70 to 91
minutes, but these differences were not statisti-
cally signiﬁcant (Kruskal-Wallis P =0.274). As
such, the overall median time is reported as 75.5
minutes (inter-quartile range: 76.5). Median time
for the specimen to be processed by the laboratory
increased from 61 and 58 minutes (inter-quartile
ranges: 31.5 and 23.5) in the ﬁrst 2 audit cycles to
70 minutes (inter-quartile range: 38.25) in the
third cycle (P< 0.001).
For all doses that were delivered at the correct
dose and frequency, all pre-dose levels were
found to be below 1mg/L.
Discussion
In our population of patients we found 40% to be
obese and, as such, the tailored prescribing of gen-
tamicin is necessary to avoid over dosing a large
number of patients. However, in our ﬁrst audit
since individualized dosing was introduced, less
than 60% of obese patients had all doses calculated
correctly requiring the development of an online
calculation tool.
Although the second audit occurred after the
introduction of the online calculator, it was clear
from reviewing prescription charts that the
majority of errors were still resulting from
doctors attempting to calculate the dosage using
the formulas on the chart. Through further edu-
cation of the doctors at induction and by altering
the prescription chart to remove the calculation
and highlight the online calculator, the frequency
of correct calculation increased to 80%, similar to
that seen in non-obese patients. The remaining
errors appear to primarily be related to doctors
estimating the dosage and then subsequent pre-
scriptions copying the error. These errors may be
prompted by attempts at dosing when patient
variables remain unknown, and so the future
focus of improvements in prescribing must
include further education of both doctors and
nursing staff to ensure that patient weight and
renal function are known early during acute
admissions.
A similar trend was seen with regards to fre-
quency calculations. The frequency at which gen-
tamicin is given should change as the patient’s
renal function varies according to the protocol.
In the ﬁrst audit cycle, errors occurred in 12.8%
of obese patients during frequency prescribing.
Following introduction of the calculator and edu-
cation, this ﬁgure was improved in the two sub-
sequent audits.
In order for gentamicin to be used safely it is
important to measure the serum gentamicin
levels. Pre-dose levels are taken 1 hour before the
dose is due. Over the 3-year period, ﬁndings
Figure 2
% of patients with an incorrectly calculated frequency according to
protocol
Figure 1
% of patients prescribed an incorrect dose according to protocol
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4were that more than 50% of results were available
to ward staff 2.5 hours after they took the blood
sample. These results demonstrate that within
this hospital it is possible to aim for all doses to
be given within 2 hours of the prescription time.
However, for other hospitals to adopt a similar
protocol it would be important to consider the
capacity of phlebotomy staff, nursing staff, porter-
ing staff and the pathology laboratory to ensure
that the samples are able to be processed urgently
enough to allow for timely dosing.
We found that when Gentamicin dose and fre-
quency was calculated according to the protocol,
there were no instances where the pre-dose level
was above 1 mg/L, suggesting that this protocol
provides safe dosing.
When used, doctors reported the online calcu-
lator to be very popular, reducing the time taken
to use the protocol. Many doctors had previously
worked in trusts where long calculations were
required for intravenous gentamicin dosing.
Some of these trusts reportedly used printed stick-
ers or booklets to aid doctors with calculations,
but no literature is available on this. Some
doctors reported instances in other hospitals
where no clear guidance existed on safe dosing.
These doctors reported feeling more able to pre-
scribe safely when using the calculator.
Conclusion
With the increasing incidence of obesity it is also
important to identify a practical way of dosing
gentamicin so that all patients are provided with
therapeutic dosages and protected from the
adverse effects of higher doses. Within the
environment of an NHS hospital it has been poss-
ible to measure the majority of serum gentamicin
levels within a 2.5 hour time frame. Such a turn-
around time suggests that protocols that dose
according to patient serum levels are feasible in
an NHS hospital. This data also demonstrates
that through the introduction of a simple online
calculator, the accuracy of prescribing in obese
patients could be improved to the same levels as
in non-obese patients. With the predicted increase
in the requirement for tailored prescribing in the
future, technological support is vital in the busy
clinical environment.
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5Appendix
UH Bristol Adult Once Daily Gentamicin Prescribing and Monitoring Policy
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6Gentamicin should be prescribed as an infusion in 100 ml sodium chloride 0.9% or glucose 5% over
30 minutes.
All patients on gentamicin should be on a ﬂuid chart.
Bloods for gentamicin levels should be sent as urgent.
Please review all IV treatment after 48 hours, and no patient should be given gentamicin for greater than 7 days
without discussion with Microbiology
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7Once Daily Gentamicin Dosing Monitoring and Interpretation of Levels
Monitoring
On the request form please state clearly the exact time when the last dose of gentamicin was given and when the
sample was taken.
• Take pre-dose gentamicin level up to 1 hour before the second dose is due. NB Random level moni-
toring is NOTrecommended.
• Collect blood in a clotted tube (yellow top).
• Pre-dose levels of gentamicin should be less than 1mg/L.
• In a patient less than 65 years, if the creatinine clearance is normal and stable, with good urine
output (>0.5 ml/kg/hr), give the second dose WITHOUT WAITING for the result. The result
should be checked and interpreted before the third dose is due to be given.
• In a patient greater than 65 years old, or with abnormal renal function, or poor urine output,
AWAIT THE RESULT before proceeding with the second dose.
• There is no need to measure peak (post dose) serum levels.
Subsequent Monitoring
• For patients with normal and stable renal function check pre-dose gentamicin levels every 48 hours.
• For patients with abnormal renal function a pre-dose serum gentamicin level is required before each
dose is given.
• In a patient less than 65 years, if the creatinine clearance is normal and stable, the patient has good
urine output (>0.5 ml/kg/hr), and previous levels have been in range the next dose can be given
without waiting for the result.
• Renal function must be checked regularly – at least three times a week. If renal function deteriorates,
more frequent monitoring may be needed, and the dosing interval may need to be increased or dis-
continuation of therapy may be required. Please discuss with Microbiology.
Please reviewall IV treatment after 48 hours, and no patient should be given gentamicin for greater
than 7 days without discussion with Microbiology
Interpretation of levels
RESULT ACTION
Pre-dose level ≤1m g /L Continue current therapy.
Pre-dose level HIGH
>1mg/L
If any pre-dose level is >1m g /L then withhold next dose and check for
reason why e.g. incorrect dosage or timing of sample.
If timing was incorrect, recheck the level at the appropriate time.
If the timing of the sample was correct then:
• The pre-dose gentamicin level must be 1mg/L or less before a further
dose is given.
• Levels will need to be repeated at 12–24 hours depending on the original
result.
• It may be necessary to increase the dosing interval.
• Any treatment changes should be discussed with the Microbiologist or
Pharmacist as continuing therapy may not be appropriate.
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8Figure 1
Obesity categorization for MALE patients. If the patient falls in the red shaded area, then they are cate-
gorized as obese (>20% above IBW) – use ﬁgure 3 to determine the dose of gentamicin to be used. For
those who fall in the green shaded area, use the actual body weight to calculate the dose of gentamicin,
as in stage 3a. The IBW for males is calculated using:
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9Figure 2
Obesity categorization for FEMALE patients. If the patient falls in the red shaded area, then they are
categorized asobese (>20%above IBW) – use ﬁgure4 to determine the dose of gentamicin to beused. For
those who fall in the green shaded area, use the actual body weight to calculate the dose of gentamicin,
as in stage 3a. The IBW for females is calculated using:
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10Figure 3
Use the height and actual body weight to determine the once daily dose of gentamicin (in milligrams) for
obese MALE patients
Figure 4
Use the height and actual body weight to determine the once daily dose of gentamicin (in milligrams) for
obese FEMALE patients
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11Recommended dose of once daily gentamicin
(in milligrams) for obese individuals (more than
20% above ideal body weight) is derived by calcu-
lating the Ideal Body Weight (IBW) as described
above, and then calculating the dose determining
weight (DDW) (kg)=IBW +0.4 × (actual body
weight (kg)− IBW).
The dose of gentamicin is then calculated by
multiplying the DDW (kg) by 5mg, then rounding
down to the nearest multiple of 40.
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